Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Accumulated Expenses: 2023-2024

  • Tonix Pharmaceuticals Holding's Accumulated Expenses was N/A to $33,000 in Q2 2024 from the same period last year, while for Jun 2024 it was $33,000, marking a year-over-year change of. This contributed to the annual value of $44,000 for FY2023, which is N/A change from last year.
  • Tonix Pharmaceuticals Holding's Accumulated Expenses amounted to $33,000 in Q2 2024, which was down 25.00% from $44,000 recorded in Q4 2023.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Accumulated Expenses ranged from a high of $44,000 in Q4 2023 and a low of $32,000 during Q3 2023.
  • For the 2-year period, Tonix Pharmaceuticals Holding's Accumulated Expenses averaged around $36,333, with its median value being $33,000 (2024).